{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260416511020/en/Janux-Therapeutics-Announces-First-Participant-Dosed-in-Phase-1-Study-of-JANX014", "message": "News view counter 667342 successfully enlarged"}